|Study Description:||The goal of this clinical research study is learn more about the safety of |
SGN-35 (brentuximab vedotin) in patients who participated in 2009-0851, were on
placebo, and whose HL has gotten worse. Another goal of this study is to allow
other patients with HL and ALCL whose disease has come back or is not getting
better on another treatment, access to brentuximab vedotin.